EZZ Life Science Holdings Ltd. stock analysis
Want to see AU:EZZ full AI Analyst Report?
EZZ Life Science Holdings Ltd. (EZZ) Share Price & Analysis
EZZ Stock Chart & Stats
- Day’s Range
- AUD 0.30 - AUD 0.30
- 52-Week Range
- AUD 0.29 - AUD 2.60
- Previous Close
- AUD 0.30
- Volume
- N/A
- Average Volume (3M)
- 15.76K
- Market Cap
- AUD 14.11M
- Enterprise Value
- AUD 7.93M
- Total Cash (Recent Filing)
- AUD 9.72M
- Total Debt (Recent Filing)
- AUD 478.59K
- Price to Earnings (P/E)
- ―
- Beta
- 1.31
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Nov 24, 2025
- Dividend Yield
- 13.53%
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage
Very low leverage limits debt-related financial risk and preserves flexibility during operational volatility. A stronger equity-funded balance sheet can support investment, absorb temporary losses, and give management more time to restore profitability without heavy refinancing pressure.
Healthy Gross-margin Base
A gross margin near 55.7% indicates the portfolio still retains meaningful economic value before operating costs. If revenue execution improves, this margin base could support operating recovery, although sustaining it will depend on pricing, product mix, and cost control.
History Of Profitable Cash Conversion
The company’s earlier record of profitability and broadly aligned free cash flow suggests that the latest cash weakness is a significant deterioration from an established operating base. That history provides evidence of potential recovery if earnings and revenue stabilize.
Bears Say
Sharp Revenue And Earnings Deterioration
The sharp revenue contraction and shift into a net loss weaken the company’s earnings trajectory and reduce internally generated funds for growth. Sustained top-line pressure would make it harder to leverage the product portfolio and could prolong the return to profitability.
Negative Operating And Free Cash Flow
Cash consumption while reporting a loss increases execution and funding risk, even with low leverage. If negative operating and free cash flow persist, management may have less capacity to reinvest, support distributions, or withstand further weakness without using balance-sheet resources.
Material Margin Compression
The decline in gross margin suggests that weaker pricing, product mix, or higher costs reduced the profitability available to cover operating expenses. This makes revenue recovery less valuable unless margin performance also improves, placing greater pressure on execution and cost discipline.
EZZ Life Science Holdings Ltd. News
EZZ Life Science Balances China Headwinds With Expansion, Governance Reset and Strong Cash Position
EZZ Life Science Holdings Ltd. ( ($AU:EZZ) ) just unveiled an announcement. EZZ Life Science Holdings reported a challenging December 2025 quarter marked by softer market conditions and heightened competition
EZZ FAQ
What was EZZ Life Science Holdings Ltd.’s price range in the past 12 months?
What is EZZ Life Science Holdings Ltd.’s market cap?
When is EZZ Life Science Holdings Ltd.’s upcoming earnings report date?
How were EZZ Life Science Holdings Ltd.’s earnings last quarter?
Is EZZ Life Science Holdings Ltd. overvalued?
Does EZZ Life Science Holdings Ltd. pay dividends?
What is EZZ Life Science Holdings Ltd.’s EPS estimate?
How many shares outstanding does EZZ Life Science Holdings Ltd. have?
What happened to EZZ Life Science Holdings Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of EZZ Life Science Holdings Ltd.?
What is the TipRanks Smart Score and how is it calculated?
EZZ Life Science Holdings Ltd. Stock Smart Score
Company Description
EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territories. The company's operations are divided into two distinct segments: 'Brought in Lines' and 'Company Owned products.' EZZ is actively involved in the wholesale supply of its EAORON-branded skincare portfolio, distributing it to pharmacies, major supermarkets, specialist retailers, and general grocery stores. Furthermore, the company designs, develops, manufactures, and markets a comprehensive selection of consumer health products under its own EZZ brand. This extensive offering includes vitamins, dietary supplements, sports nutrition, weight management and wellbeing solutions, traditional herbal remedies, and paediatric lines. These EZZ-branded items are sold directly to consumers via its e-commerce platforms and various retail stores, notably Tmall Global. Founded in 2015, EZZ Life Science Holdings Limited maintains its corporate headquarters in Silverwater, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Qizhou Qin
- Employees
- 11
- Website
- ezzlife.com.au
- Address
- Shop 1, 55-59 Parramatta Road, Lidcombe, NSW, 2141, AU
EZZ Life Science Holdings Ltd. (EZZ) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 12 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 3 | 0 | 9 |
